Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright

Prime Medicine, Inc. (NASDAQ:PRME) – Equities researchers at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Prime Medicine in a note issued to investors on Monday, August 10th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Prime Medicine’s Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.11) EPS, Q2 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($0.92) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at ($0.81) EPS.

Several other research analysts have also commented on PRME. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research note on Wednesday, June 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Prime Medicine in a research note on Monday, June 22nd. Wall Street Zen upgraded shares of Prime Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday. The Goldman Sachs Group set a $6.00 price target on shares of Prime Medicine in a research report on Monday, June 22nd. Finally, TD Cowen restated a “buy” rating on shares of Prime Medicine in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.53.

Prime Medicine Price Performance

Shares of NASDAQ:PRME opened at $3.26 on Wednesday. The firm has a market capitalization of $591.30 million, a PE ratio of -3.08 and a beta of 2.31. The firm’s 50-day moving average is $3.27 and its two-hundred day moving average is $3.47. Prime Medicine has a 1 year low of $2.67 and a 1 year high of $6.94.

Prime Medicine (NASDAQ:PRME) last announced its earnings results on Thursday, August 6th. The company reported ($0.24) EPS for the quarter, meeting analysts’ consensus estimates of ($0.24). The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $4.40 million. Prime Medicine had a negative return on equity of 156.84% and a negative net margin of 4,613.11%.

Hedge Funds Weigh In On Prime Medicine

Several hedge funds and other institutional investors have recently made changes to their positions in PRME. Redmile Group LLC purchased a new stake in shares of Prime Medicine during the first quarter worth approximately $5,536,000. ADAR1 Capital Management LLC acquired a new stake in Prime Medicine in the first quarter valued at approximately $6,867,000. UBS Group AG raised its holdings in Prime Medicine by 700.8% in the fourth quarter. UBS Group AG now owns 2,440,583 shares of the company’s stock valued at $8,469,000 after acquiring an additional 2,135,810 shares in the last quarter. MWG Caph Ltd purchased a new position in Prime Medicine in the fourth quarter worth approximately $6,219,000. Finally, Chelsea Counsel Co. grew its holdings in Prime Medicine by 103.7% during the 1st quarter. Chelsea Counsel Co. now owns 462,340 shares of the company’s stock worth $1,609,000 after acquiring an additional 235,340 shares in the last quarter. Hedge funds and other institutional investors own 70.37% of the company’s stock.

Key Prime Medicine News

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Prime Medicine announced that it is advancing PM577 into a first-in-human clinical study for Wilson disease. Progress toward human testing could improve investor confidence in the company’s prime-editing platform and pipeline. Prime Medicine Advances First-in-Human Prime Editing Trial in Wilson Disease
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $8.00 price target for PRME, substantially above the stock’s referenced $3.26 price. The continued bullish rating provides a positive analyst signal despite ongoing losses. HC Wainwright Reaffirms Buy Rating for Prime Medicine
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast from a loss of $1.17 to a loss of $1.11 and improved its FY2028 forecast from a loss of $1.01 to $0.92 per share, suggesting modestly better long-term cost or earnings expectations in those periods.
• Neutral Sentiment: HC Wainwright made only minor adjustments to several forecasts, including a slightly better Q3 2026 estimate of a $0.28 loss, but maintained expectations for continued losses through 2030. The changes are unlikely to materially alter the near-term valuation story.
• Neutral Sentiment: The reported short-interest data showed zero shares sold short both before and after the measurement period, making the figures unusable for identifying meaningful short-covering or short-squeeze pressure.
• Negative Sentiment: HC Wainwright lowered its estimates for Q2 2027, Q4 2026, FY2027, FY2029 and FY2030. The largest revisions were FY2029, to a $0.96 loss from $0.85, and FY2030, to a $0.81 loss from $0.67, reinforcing concerns about prolonged cash burn and delayed profitability.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.